Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucidi Bruno Insider Profile
4 Followers
Lucidi Bruno, Director at Atea Pharmaceuticals, holds ― shares in Atea Pharmaceuticals (Ticker: AVIR). Most recently, Lucidi Bruno ― shares of Atea Pharmaceuticals on ― for an estimated value of ―.
Lucidi Bruno has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Lucidi Bruno does not currently own shares as a corporate insider.
A breakdown of Lucidi Bruno's holdings
Insider Roles
Director
Roles that Lucidi Bruno holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Lucidi Bruno
Lucidi Bruno's Trading History
List of latest transactions for each holding click on a transaction to see Lucidi Bruno's performance on stock
You May Also Like
Lucidi Bruno insider profile FAQ
What is the percentage of profitable transactions made by Lucidi Bruno?
The percentage of profitable transactions made by Lucidi Bruno is ―.
What is the average return per transaction made by Lucidi Bruno?
The average return per transaction made by Lucidi Bruno is ―.
What stocks does Lucidi Bruno hold?
Lucidi Bruno holds: AVIR stocks.
What was Lucidi Bruno’s latest transaction?
Lucidi Bruno latest transaction was an Uninformative Buy of ―.
What was Lucidi Bruno's most profitable transaction?
Lucidi Bruno’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Lucidi Bruno's role in Atea Pharmaceuticals?
Lucidi Bruno's role in Atea Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.